Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 05 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Validation of endoscopic activity scores in patients with Crohn's disease

A post hoc analysis reported in November's issue of Gastroenterology validates endoscopic activity scores in patients with Crohn's disease.

News image

Mucosal healing might alter midterm and long-term outcomes of patients with Crohn's disease (CD) and has become an important end point in clinical trials.

However, the minimal degree of mucosal improvement (endoscopic response) required to alter midterm outcomes is not known.

Dr Marc Ferrante and colleagues from Belgium determined the best definition of endoscopic response by evaluating data on the Simple Endoscopic Score for Crohn's Disease (SES-CD), and the Crohn's Disease Endoscopic Index of Severity (CDEIS) from the Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease (SONIC trial).

The researchers analyzed data from 172 patients who participated in the SONIC trial, were found to have endoscopic lesions at baseline, and underwent a second endoscopic examination at week 26 of treatment with infliximab, azathioprine, or both.

The team defined mucosal healing as absence of ulcers.

The relative risk was 0.80 for an increment of 1 cup of coffee per day
Gastroenterology

A central reader calculated SES-CD and CDEIS results.

Different cutoff values were set for endoscopic response based on the SES-CD or CDEIS.

The diagnostic ability of these different cutoff values was evaluated using receiver operating characteristic curves, positive likelihood ratios, and negative likelihood ratios.

Corticosteroid-free clinical remission (CFREM) at week 50 was used as a binary classifier.

Based on analyses of ROC curves, positive likelihood ratios, and negative likelihood ratios, endoscopic response was defined as a decrease from baseline in SES-CD of at least 50%.

The research team found that at week 26, mucosal healing and endoscopic response were achieved in 48% and 65% of patients, respectively.

Mucosal healing at week 26 was associated with CFREM at week 50, with 56% sensitivity, 65% specificity, a positive likelihood ratios of 1.60, and an negative likelihood ratios of 0.67.

Endoscopic response at week 26 was associated with CFREM at week 50, with 74% sensitivity, 48% specificity, a positive likelihood ratios of 1.42, and an negative likelihood ratios of 0.54.

The team observed that endoscopic response, defined as a decrease from baseline in CDEIS of at least 50%, yielded similar results.

Dr Ferrante's team concludes, "In patients with Crohn's disease, mucosal healing and endoscopic response at week 26 of treatment identified those most likely to be in CFREM at week 50."

"The ability of the proposed endoscopic response cutoff value to predict midterm CFREM should be validated in an independent, prospective cohort."

"Its correlation with changes in long-term disease progression still needs to be demonstration."

Gastroenterol 2013: 145(5): 978-986.e5
25 October 2013

Go to top of page Email this page Email this page to a colleague

 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 05 December 2016 
Reducing hospitalization in IBD
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 23 November 2016 
Quality assurance standards for colonoscopy
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 21 November 2016 
Financial incentives and colorectal cancer screening
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 17 November 2016 
Liver-related specialty care in patients with Hep C
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Physician perspectives on Hep C management
 15 November 2016 
Contraceptives and ulcerative colitis
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression
 10 November 2016 
Testosterone levels and cirrhosis outcomes in men
 10 November 2016 
Improving bowel quality before colonoscopy
 10 November 2016 
Fecal microbiota transplantation and CDI episodes
 09 November 2016 
Minimizing costs of esophagogastroduodenoscopy and colonoscopy
 09 November 2016 
Risk of TB in IBD patients receiving therapy
 09 November 2016 
Liver transplant wait-list and mortality in infants
 08 November 2016 
NSAIDS and risk of Barrett’s
 08 November 2016 
Ferritin levels and NAFLD mortality
 08 November 2016 
Alarms in the diagnosis of colorectal cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us